Dual epigenetic agents plus rituximab–gemcitabine–oxaliplatin as salvage treatment in relapsed/refractory diffuse large B‐cell lymphoma patients failure of salvage chemotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3052
Abstract: Refractory/relapsed (R/R) diffuse large B‐cell lymphoma (DLBCL) patients' failure of salvage chemotherapy had extremely worse prognoses. Herein, 14 R/R DLBCL patients failed to salvage chemotherapy were exposed to dual epigenetic agents (Chidamide 30 mg biw*2w… read more here.
Keywords: dual epigenetic; salvage chemotherapy; diffuse large; epigenetic agents ... See more keywords